

# Fully Licensed Swiss Cannabis Producer with GACP Cultivation and GMP Manufacturing Capabilities





## Fully Licensed Swiss Cannabis Producer with GACP Cultivation and GMP Manufacturing Capabilities

A Swiss company with a rare license to produce weed and medical cannabis is up for sale.

The company's purpose is the **breeding, research, production, and trade of plants for medical and pharmaceutical application** as well as the **production, distribution, and trade of pharmaceutical and medical products**.

The company may establish branch offices and subsidiaries at home and abroad, participate in other companies at home and abroad, acquire, hold, exploit, and sell intellectual property rights, and carry out all business that is directly or indirectly related to its purpose.

The company may acquire, encumber, sell, and manage real estate at home and abroad. It may also undertake financing for its own or third-party accounts, and enter into guarantees and sureties for subsidiaries and third parties.

### Permits/Authorisations

The company holds all necessary permits in Switzerland for the medical cannabis sector.

Thanks to these permits, it is able to cultivate itself, store, purchase goods, import, trade, commission, and distribute its products directly within Switzerland.

The permits were granted by Swissmedic, the responsible Swiss Authorising and Controlling Authority for therapeutic products. The production facility was inspected and approved by the Cantonal Pharmacist and has been approved by the GMP (Good Manufacturing Practice) department of the Regional Institute for Medicines (RHI), thereby fulfilling all regulatory requirements for operation.

### Production Field

A multi-room cultivation facility, including dedicated mother plant areas optimized for consistent, pharmaceutical-grade production.

### Resellers / Network

Through its control over the entire production chain and wholesale trade, this firm has the unique opportunity to tap into the entire Swiss market for medical and pharmaceutical cannabis.

– **1,800 pharmacies in Switzerland:** offers a premier foundation for significant commercial growth. Our successful early market entry via leading Swiss pharmacy channels demonstrates market readiness of the business model and supports national scaling.

Operational execution will be led by an **experienced sales expert** with an established network within the pharmacy sector. This individual will be specifically responsible for building and managing distribution channels. To ensure maximum market penetration, we are currently evaluating the optimal structure for this collaboration—whether as an independent intermediary or through a permanent employment contract.

### BUSINESS TYPE

Manufacturing

### COUNTRY

Switzerland

### BUSINESS ID

L#20251050

- Potential partnership with a B2B pharmaceutical wholesaler (e.g., Galexis and Co.).

## Licence

### Original

#### **Betriebsbewilligung zum Anbau von Cannabis für medizinische Zwecke.**

(Art. 2 Bst. h BetmKV)

- **Betriebsbewilligung zum Umgang mit kontrollierten Substanzen.**

(Art. 2 Bst. h BetmKV)

- **Betriebsbewilligung Arzneimittel**

(Bewilligungsnummer XXXXXX-XXXXXX)

#### **Die Bewilligung wird für folgende Tätigkeiten erteilt:**

- Herstellung von Arzneimitteln
- Grosshandel mit Arzneimitteln

#### **Gesetzliche Grundlagen:**

- Heilmittelgesetz (HMG; SR 812.21)
- Arzneimittel-Bewilligungsverordnung (AMBV; SR 812.212.1)
- Arzneimittelverordnung (VAM; SR 812.212.21)
- Lohnerstellung laut Heilmittelgesetz (HMG)

### English

#### **Operating License for the Cultivation of Cannabis for Medical Purposes.**

(Art. 2 lit. h Narcotics Control Ordinance)

- **Operating License for the Handling of Controlled Substances.**

(Art. 2 lit. h Narcotics Control Ordinance)

- **Medicinal Products Operating License**

(License Number XXXXXX-XXXXXX)

#### **The license is granted for the following activities:**

- Manufacturing of Medicinal Products
- Wholesale of Medicinal Products

#### **Legal Basis:**

- Therapeutic Products Act (HMG; SR 812.21)
- Ordinance on the Licensing of Medicinal Products (AMBV; SR 812.212.1)
- Medicinal Products Ordinance (VAM; SR 812.212.21)
- Contract Manufacturing (Toll Manufacturing) according to the Therapeutic Products Act (HMG)

## Infrastructure

The company benefits from a cost-efficient production by leasing space and being able to optimally utilize the existing infrastructure.

Its landlord recently offered it the prospect of leasing additional space in the building. A 10-year rental agreement has been secured at very favorable conditions.

## Human Resources

There are 2 employees and 3 freelancers. Its team has been in place for 10 years and possesses comprehensive experience.

## Rapid Scalability

Thanks to the existing know-how and the possibility of leasing additional production space the company can quickly respond to demand.

## Swiss Made

This allows it to access the international market with its high-quality flowers. To the company's knowledge, no Swiss player is currently active on the global market with their own products.

*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

[www.mergerscorp.com](http://www.mergerscorp.com)



© 2024 MergersCorp M&A International. All rights reserved.

*© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.*



[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)